Business Wire

Hotwire Ignite Possibility Program Introduces the First Group of Tech-enabled DEI Innovators

30.6.2021 16:00:00 EEST | Business Wire | Press release

Share

Hotwire, the leading global technology communications consultancy part of Enero Group, has announced the first set of participating companies in the Hotwire Ignite Possibility Program (HIPP). Launched earlier this year, HIPP is providing $1 million USD in pro bono brand marketing and public relations services to tech and tech-enabled organizations led by or supporting minority communities. This program is part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to amplify people and organizations creating meaningful and sustainable change in the world through technology innovation.

After a rigorous review process of nearly 100 applicants, including in-depth interviews with a short list of finalists, the first group of participating companies includes for-profit and nonprofit organizations in the consumer and B2B technology industries with headquarters in the United States and United Kingdom. HIPP participants from our other European offices and Australia will be announced in the coming months.

The six initial participating companies are:

  • Children’s Creativity Musuem , a nonprofit organization offering hands-on, multimedia arts and technology experiences to build children’s creative confidence.
  • Full Circle Fund , a nonprofit community leveraging professionals’ financial and intellectual capital to accelerate nonprofits and build a better San Francisco Bay Area.
  • Go Flyy , an on-demand, same-day delivery and returns service for fashion, beauty and wellness products, currently operating in Los Angeles, New York City and Seattle.
  • Husmus , an online service that aims to make renting easy and affordable in order to build a world where everyone can enjoy renting privately.
  • Menther , a digital platform helping to empower and advance women globally through cross and intra-generational mentorship matching and support.
  • Storyskimo , an online platform leveraging audio and podcasting as a language and learning development tool for children.

Additionally, as part of HIPP, our Spain office has launched an industry collaborative think tank, Margarita Bly , that is working to pave the way for more female communicators of science, technology and innovation, and encourage more girls and young women to pursue STEM careers.

“We are thrilled to announce the first class of participants in the Hotwire Ignite Possibility Program and look forward to supporting the communications goals of this impressive group of companies,” said Heather Kernahan, Global CEO, Hotwire. “This program is a critical part of Hotwire’s Diversity, Equity, and Inclusion (DEI) strategy to direct more of our resources towards the advancement of social justice in our industry.”

Teams from Hotwire’s global offices will be working with the selected organizations to address their specific business needs through customized programs that include brand strategy, marketing, and public relations services.

“We are honored to be selected as a HIPP participant and so excited to work with a world-class technology communications agency like Hotwire. Children’s Creativity Museum’s mission to nurture creativity and collaboration in all children and families, specifically those in socially and economically disadvantaged communities, is well-aligned with the program goals,” said Carol M. Tang, Ph.D., Executive Director, Children’s Creativity Museum. “We can’t wait to get started.”

“As a female minority co-founder who benefited from mentorship early on in my own career, I’m thrilled to be working with Hotwire to help us scale Menther so more women can have easy access to the power of mentorship,” said Vanessa Villaverde, Menther. “We know this partnership is going to be game changing for us in our reach and impact at a time when women who have been economically impacted by COVID-19 need support the most,” Menther Co-Founder Lesli Ott said.

“We truly believe that no matter who you are or what background you come from, you should be able to access safe and secure housing without having to worry about your credit history or the upfront costs involved,” said Sarah Wernér, Founder of Husmus. “The team and I have worked really hard to create a product that solves a big problem. However, we recognise while we have great technical experience, we do not have the marketing skills to make sure that we are able to reach the many people who need us. Working with Hotwire gives us access to expertise that we otherwise would not have at this early stage and we can’t wait to kick things off,” Husmus’ founder Sarah Wernér said.

About Hotwire

Hotwire is the global technology communication consultancy, part of the Enero Group. Founded in 2000, we operate a worldwide network of wholly owned offices and partners serving a range of clients from scale ups to established multi-nationals. We unleash the possibilities of innovative technology through integrated communications that ignite curiosity, spark action and fuel success. We do this using our proprietary methodology which is underpinned by robust insight and strategy, purposeful creative, integrated planning and a core emphasis on measurement and evaluation. www.hotwireglobal.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kelsey Quickstad
kelsey.quickstad@hotwireglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye